Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03518632
Other study ID # 2017-A02992-51
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 27, 2018
Est. completion date March 31, 2020

Study information

Verified date July 2020
Source Centre Hospitalier Universitaire de Besancon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to assess the impact of preoperative physical activity on physical capacities of patients undergoing liver resection for primary or secondary liver cancer.


Description:

The purpose of this study is to investigate the effects of a preoperative exercise program in patients with primary or secondary liver cancer undergoing hepatectomy. Preoperative exercise programs have been shown to be effective in other cancer populations, but have been poorly studied in patients with liver cancer. For these patients, it remains unclear what the optimal composition of such programs should be and how they should be delivered. Outcome measures in this study will include preoperative outcomes (oxygen consumption, quality of life, fatigue and physical activity level, anthropometric measures, plasma concentrations of hepatokines) and postoperative outcomes (length of hospital stay and postoperative complications). After the study is explained and consent obtained, subjects will be tested on a submaximal exercise on cycloergometer with gas exchanges analysis and with pre and post blood test. Then, they will answer various questionnaires assessing physical activity, quality of life and fatigue. Patients scheduled for liver resection will be randomized to one of two groups. The first group (experimental group) will be subdivided into two groups: interval training 1 and interval training 2, which differentiate themselves by two different intensities.The second group (control group) will receive standard care. The prehabilitation program will last 6 weeks with 3 sessions per week and will consist in two interval training programs on a cycloergometer with two different intensities. One month after surgery, peri and postoperative complications will be noted.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date March 31, 2020
Est. primary completion date March 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women aged >18 years old. - Patients with primary liver cancer, biliary tract cancer, liver metastasis endorsed in the University Hospital of Besancon - No opposition of patients - Join a French social security or receiving such a scheme Exclusion Criteria: - Legal incapacity or limited legal capacity - Patients being in the disqualification of another study or under the national register of volunteers - Patients unlikely to cooperate or anticipated low cooperation - Patients with a maximal oxygen consumption above 35 ml/min/kg

Study Design


Intervention

Behavioral:
Interval training
Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.
Other:
Standard Oncologic care
Patients in control group will follow the standard oncologic care. They will perform only 2 sub-maximal exercises.

Locations

Country Name City State
France Chirurgie digestive, viscérale et cancérologique Besançon

Sponsors (1)

Lead Sponsor Collaborator
Célia Turco

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of Oxgen consumption at anaerobic threshold : Oxygen consumption at anaerobic threshold will be assessed at baseline and at the end of the 6 weeks' program with a submaximal exercise performed on cycloergometer 6 weeks
Secondary Postoperative complications with the Dindo Clavien classification : Postoperative complications will be assessed using the Dindo Clavien classification which consists in a 7 grades classification (I, II, IIIa, IIIb, IVa, IVb and V). One month after surgery
Secondary Intensive care stay : Postoperative intensive care stay will be evaluated (number of days). One month after surgery
Secondary Changes of Hepatokines plasmatic concentrations : Fetuin A (ng/mL) concentrations will be analyzed. Comparison between plasmatic concentrations pre-exercise (day 1), post exercise (day 1) and at 6 weeks
Secondary Hepatokines plasmatic concentrations : Fibroblast Growth Factor 21 (FGF21) (pg/mL) concentrations will be analyzed. Comparison between plasmatic concentrations pre-exercise (day 1), post exercise (day 1) and at 6 weeks
Secondary Changes in Physical activity level : Physical activity level will be measured using the long-form of the International Physical Activity Questionnaire (IPAQ). It consist in a description of the physical activity level by assessing 5 activity domains during the 7 last days. Physical activity level is expressed in Metabolic Equivalent Tasks (METs). It enables to classify patients in 3 categories : low physical activity level, moderate physical activity level and high physical activity level. Comparison between baseline, after the 6 weeks' program
Secondary Changes in Quality of life : Health related quality of life will be measured with the EORTC Quality of Life Questionnaire QLQ-C30 which is a cancer specific questionnaire. It consists in 30 items to measure 15 dimensions of quality of life. It generates a score between 0 and 100. A higher score means a higher quality of life level. Comparison between baseline, after the 6 weeks' program
Secondary Changes in Fatigue : Fatigue will be measured with the Quality of Life Questionnaire QLQ-FA12 which enables to assess cancer related fatigue. It consists in 12 items to measure 5 dimension go health related fatigue. It generates a score between 0 and 100. A higher score means a higher fatigue level. Comparison between baseline, after the 6 weeks' program
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT04837885 - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases Phase 2
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Not yet recruiting NCT04520737 - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases N/A
Terminated NCT02465112 - Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor Phase 3
Completed NCT02352259 - Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II Phase 2
Active, not recruiting NCT01763450 - Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer Phase 2
Withdrawn NCT01631539 - Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC N/A
Recruiting NCT01250158 - Liver-PILP First-in-Man N/A
Terminated NCT01233544 - Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases Phase 3
Completed NCT01347333 - Stereotactic Body Radiotherapy for Liver Tumors N/A
Completed NCT01683357 - Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases N/A
Completed NCT00587756 - Alternative to Two-Stage Hepatectomy N/A
Completed NCT04942665 - Low Dose ICG for Biliary Tract and Tumor Imaging Phase 2
Not yet recruiting NCT05354674 - Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
Recruiting NCT04616495 - Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
Not yet recruiting NCT04509635 - Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis Phase 3